Vanguard Group Inc Phase Bio Pharmaceuticals Inc Transaction History

Vanguard Group Inc

  • $5.12 Trillion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
SELL
$0.52 - $1.59 $9,377 - $28,672
-18,033 Reduced 0.99%
1,808,098 $1.09 Million
Q1 2022

May 13, 2022
SELL
$0.97 - $2.66 $8,508 - $23,333
-8,772 Reduced 0.48%
1,826,131 $2.41 Million
Q4 2021

Feb 14, 2022
SELL
$1.9 - $4.05 $75,373 - $160,663
-39,670 Reduced 2.12%
1,834,903 $4.79 Million
Q3 2021

Nov 12, 2021
BUY
$2.72 - $3.85 $16,072 - $22,749
5,909 Added 0.32%
1,874,573 $5.83 Million
Q2 2021

Aug 13, 2021
BUY
$2.7 - $3.98 $5.05 Million - $7.44 Million
1,868,664 New
1,868,664 $6.95 Million

About PhaseBio Pharmaceuticals Inc

PHAS Quotes by TradingView
  • Ticker PHAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,858,100
  • Description
  • PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or li...
More about PHAS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email